Oversight Dems Call WH Drug Policy Goals Modest, GAO Wants More Info

By Chelsea Cirruzzo / May 9, 2019 at 2:43 PM
The Government Accountability Office (GAO) said it still hasn’t received documents from the White House Office of National Drug Control Policy (ONDCP) needed to adequately assess the administration’s national drug policy strategy, while some House Democrats said the goals outlined by the drug control office on medication-assisted treatment (MAT) are too modest. ONDCP Director James Carroll once again testified before the House Oversight & Reform Committee Thursday (May 9), two months after he testified on the national drug policy strategy...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.